
    
      The initiation of different stage of the study depend on the occurrences of severe toxicities
      in safety run-in phase and Clinical Benefit rate after 24 weeks in the two-stage Phase II of
      the study.

      Both study drugs will continue to be administered as long as patient experience clinical
      benefit in the opinion of the investigator or symptomatic deterioration attributed to disease
      progression as determined by the investigator after an integrated assessment of radiographic
      data and clinical status or withdrawal of consent.
    
  